PLX7922

Cat. No.:	HY-107415
CAS No.:	1638772-61-8
Molecular Formula:	$C_{20}H_{25}FN_6O_2S_2$
Molecular Weight:	464.58
Target:	Raf
Pathway:	MAPK/ERK Pathway
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (215.25 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.1525 mL	10.7624 mL	21.5248 mL
	5 mM	0.4305 mL	2.1525 mL	4.3050 mL
	10 mM	0.2152 mL	1.0762 mL	2.1525 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PLX7922, a RAF inhibitor, can bind with $BRAF^{V600E}$. PLX7922 inhibits pERK in $BRAF^{V600E}$ cell lines, and activates pERK in mutant NRAS cell lines[1].

IC_{50} & Target

RAF[1]

In Vitro

PLX7922 (1-1000 nM) inhibits pERK in $BRAF^{V600E}$ cell lines, activates pERK in mutant NRAS cell lines (B9 and IPC-298)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Zhang C, et, al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015 Oct 22;526(7574):583-6.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA